Functional imaging in epilepsy

Seizure

Volumn 11, Issue SUPPL. A, 2002, Pages 139-156

  Richardson, Mark P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Epilepsy; fMRI; MRS; PET; Review; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; CARBON 11; FLUMAZENIL; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODINE 131; IOMAZENIL; PHOSPHORUS 31; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; DIAGNOSTIC AGENT; OPIATE RECEPTOR; PROTON; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN SCINTISCANNING; CLINICAL EXAMINATION; CLINICAL RESEARCH; COGNITION; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; EPILEPSY; HUMAN; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MOTOR PERFORMANCE; NEUROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ELECTROENCEPHALOGRAPHY; METABOLISM; PATHOLOGY; REVIEW; VASCULARIZATION;

ANTICONVULSANTS; BRAIN; ELECTROENCEPHALOGRAPHY; EPILEPSY; FLUORODEOXYGLUCOSE F18; GAMMA-AMINOBUTYRIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; RADIOPHARMACEUTICALS; RECEPTORS, GABA; RECEPTORS, GABA-A; RECEPTORS, OPIOID; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036014471     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2002.0679     Document Type: Editorial

References (182)

1. MRI-PET registration with automated algorithm
2. Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging
3. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects
4. Correction for partial volume effects in PET using MRI-based 3D simulations of individual human brain metabolism
5. In vivo correction for partial volume effects in PET: Accuracy and precision
6. MR-based correction of brain PET measurements for heterogeneous gray matter radioactivity distribution
7. MR-based correction of partial volume effects in brain PET imaging
8. C-11-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy
9. Cerebral benzodiazepine receptors in hippocampal sclerosis: An objective in vivo analysis
10. Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An 11C-flumazenil PET study
11. Statistical parametric maps in functional imaging: A general linear approach
12. Cortical grey matter and benzodiazepine receptors in malformations of cortical development: A voxel-based comparison of structural and functional imaging data
13. Imaging and epilepsy
14. Functional MRI applications in clinical epilepsy
15. Functional MRI in children with epilepsy
16. Spatiotemporal EEG analysis and distributed source estimation in presurgical epilepsy evaluation
17. Functional magnetic resonance imaging of focal seizures
18. Localization of subclinical ictal activity by functional magnetic resonance imaging: Correlation with invasive monitoring
19. Coupling of cortical and thalamic ictal activity in human partial epilepsy: Demonstration by functional magnetic resonance imaging
20. EEG-triggered echoplanar functional MRI in epilepsy
21. Reproducible localization of interictal epileptiform discharges using EEG-triggered fMRI
22. Identification of EEG events in the MR scanner: The problem of pulse artifact and a method for its subtraction
23. Simultaneous functional magnetic-resonance-imaging and electrophysiological recording
24. Recording of EEG during fMRI experiments: Patient safety
25. EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures
26. EEG-triggered functional MRI in patients with pharmacoresistant epilepsy
27. Echo-planar functional MR imaging of epilepsy with concurrent EEG monitoring
28. Functional magnetic-resonance-imaging in partial epilepsy
29. Functional MRI measurement of language lateralization in Wada-tested patients
30. Functional activation during an auditory comprehension task in patients with temporal lobe lesions
31. Determination of language dominance using functional MRI: A comparison with the Wada test
32. Noninvasive assessment of language dominance in children and adolescents with functional MRI: A preliminary study
33. Comparison of functional magnetic resonance imaging for language localization and intracarotid speech amytal testing in presurgical evaluation for intractable epilepsy. Preliminary results
34. Side of seizure focus predicts left medial temporal lobe activation during verbal encoding
35. Language dominance determined by whole brain functional MRI in patients with brain lesions
36. Functional MRI lateralization of memory in temporal lobe epilepsy
37. Episodic memory in left temporal lobe epilepsy: A functional MRI study
38. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
39. Magnetic resonance spectroscopy in temporal lobe epilepsy
40. 1H Magnetic resonance spectroscopy in the investigation of intractable epilepsy
41. Proton magnetic resonance spectroscopy in children with temporal lobe epilepsy
42. Temporal lobe epilepsy: Correlation of proton magnetic resonance spectroscopy and F-18-fluorodeoxyglucose positron emission tomography
43. Interictal Tc-99(m) HMPAO SPECT and H-1 MRS in children with temporal lobe epilepsy
44. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging
45. Presurgical localization of temporal lobe epilepsy using noninvasive proton chemical shift spectroscopic imaging
46. Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images
47. Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: A series of 100 patients
48. Proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1T
49. Hippocampal N-acetylaspartate in neocortical epilepsy and mesial temporal lobe epilepsy
50. Verbal memory impairment after right temporal lobe surgery: Role of contralateral damage as revealed by 1H magnetic resonance spectroscopy and T2 relaxometry
51. Lateralization of brain-function in childhood revealed by magnetic-resonance spectroscopy
52. Temporal lobe epilepsy: Presurgical localization with proton chemical shift imaging
53. Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures
54. Localized 1H NMR measurements of g-aminobutyric acid in human brain in vivo
55. Initial observations on the effect of vigabatrin on in vivo 1H spectroscopic measurements of GABA, glutamate and glutamine in human brain
56. Initial observations on the effect of gabapentin on brain GABA in patients with epilepsy
57. Increased pH and inorganic phosphate in temporal seizure foci demonstrated by [31P]MRS
58. Lateralization of human focal epilepsy by 31P magnetic resonance spectroscopic imaging
59. Single-photon tomographic determination of regional cerebral blood flow in epilepsy
60. Single photon emission computed tomography (SPECT) brain imaging using N,N,N′-trimethyl-N′-(2 hydroxy-3-methyl-5-123I-iodobenzyl)-1,3-propanediamine 2 HCl (HIPDM): Intractable complex partial seizures
61. HIPDM single photon emission computed tomography brain imaging in partial onset secondarily generalized tonic-clonic seizures
62. HIPDM-SPECT in patients with medically intractable complex partial seizures. Ictal study
63. Initial experience with 99m Tc-hexamethyl-propylene amine oxime (HM-PAO) single photon emission computed tomography (SPECT) in patients with focal epilepsy
64. Functional and morphological abnormalities in temporal lobe epilepsy: A comparison of interictal and ictal EEG, CT, MRI, SPECT and PET
65. Single photon emission computed tomography in seizure disorders
66. Quantitative assessment of cerebral blood flow in partial epilepsy using Xe-133 inhalation and SPECT
67. Hexa-methyl-propylene-amine-oxime (HMPAO) single photon emission computed tomography (SPECT) in epilepsy
68. Single photon emission computed tomography (SPECT) using N-isopropyl-p-(123I) iodoamphetamine (IMP) in the evaluation of patients with epileptic seizures
69. Visual and quantitative analysis of interictal SPECT with technetium-99m-HMPAO in temporal lobe epilepsy
70. Regional relationships between focal hypofixation images in 123I-IMP single photon emission computed tomography and epileptic EEG foci in interictal periods in patients with partial epilepsy
71. Interictal HM-PAO SPECT: A routine investigation in patients with medically intractable complex partial seizures?
72. The relative contributions of MRI, SPECT, and PET imaging in epilepsy
73. Interictal single-photon emission computed-tomography in partial epilepsy-accuracy in localization and prediction of outcome
74. HIPDM-SPECT brain imaging in the presurgical evaluation of patients with intractable seizures
75. Ictal and interictal 99mTc-HMPAO-SPECT studies in temporal lobe epilepsy with unilateral EEG focus
76. Single photon imaging computed tomography (SPECT) for localization of epileptogenic focus in patients with intractable complex partial seizures
77. Ictal SPECT using technetium-99m-HMPAO: Methods for rapid preparation and optimal deployment of tracer during spontaneous seizures
78. Ictal/postictal SPECT in the pre-surgical localisation of complex partial seizures
79. Ictal 99mTc-HMPAO single photon emission computed tomography in children with temporal lobe epilepsy
80. Ictal brain imaging in presurgical evaluation of patients with medically intractable complex partial seizures
81. Children with intractable focal epilepsy: Ictal and interictal 99TcM HMPAO single photon emission computed tomography
82. SPECT in the localisation of extratemporal and temporal seizure foci
83. Localization of extratemporal epileptic foci during ictal single photon emission computed tomography
84. Frontal lobe epilepsy: Clinical seizure characteristics and localization with ictal 99mTc-HMPAO SPECT
85. Patterns of postictal cerebral blood flow in temporal lobe epilepsy: Qualitative and quantitative analysis
86. Location of epileptic foci on interictal and immediate postictal single-photon emission tomography in children with localization-related epilepsy
87. Difference images calculated from ictal and interictal technetium-99m-HMPAO SPECT scans of epilepsy
88. Subtraction ictal SPECT coregistered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus
89. Subtraction ictal SPET co-registered to MRI in partial epilepsy: Description and technical validation of the method with phantom and patient studies
90. Cognitive function and regional cerebral blood flow in partial seizures
91. Initial experience with SPECT imaging of the brain using I-123 p-iodoamphetamine in focal epilepsy
92. Postictal switch in blood flow distribution and temporal lobe seizures
93. Reverse crossed cerebellar diaschisis in partial complex seizures related to herpes simplex encephalitis
94. SPECT in patients with epilepsia partialis continua
95. Dystonia, clinical lateralization, and regional blood flow changes in temporal lobe seizures
96. Temporal-lobe epilepsy subtypes, differential patterns of cerebral perfusion on ictal spect
97. Imaging benzodiazepine receptors in the human brain by single photon emission computed tomography (SPECT)
98. Evaluation of a multicentre study with Iomazenil-a benzodiazepine receptor ligand
99. Benzodiazepine receptors and cerebral blood flow in partial epilepsy
100. Evaluation of focal epilepsy: A SPECT scanning comparison of 123-I-iomazenil versus HM-PAO
101. Lack of effect of concomitant clobazam on interictal 123I-iomazenil SPECT
102. 123I-iomazenil- and 99mTc-HMPAO in the diagnosis of focal epilepsies: A comparison of untreated and treated patients
103. Role of I-123-iomazenil SPECT imaging in drug resistant epilepsy with complex partial seizures
104. Cortical dysplasia as an epileptogenic focus: Reduced binding of 123I-iomezanil with barely perceptible 99mTc-HMPAO SPECT
105. Comparison of benzodiazepine receptor and regional cerebral blood flow imaging of epileptiform foci in hippocampal kindled rabbits: A preliminary report
106. Dual-isotope autoradiographic measurement of regional blood flow and benzodiazepine receptor availability following unilateral middle cerebral artery occlusion
107. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: Kinetic and equilibrium paradigms
108. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters
109. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: I. Kinetic modeling of single bolus experiments
110. Increased interictal cerebral glucose metabolism in a cortical-subcortical network in drug naive patients with cryptogenic temporal lobe epilepsy
111. Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computed tomography of 18FDG and 13NH3
112. Comparative localization of epileptic foci in partial epilepsy by PET and EEG
113. Pathological findings underlying focal temporal hypometabolism in partial epilepsy
114. Interictal cerebral glucose metabolism in partial epilepsy and its relation to EEG changes
115. 18F-fluorodeoxyglucose positron emission tomography in refractory complex partial seizures
116. Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy
117. Regional cerebral blood flow and metabolic rates in human focal epilepsy and status epilepticus
118. Metabolic patterns associated with non-specific magnetic resonance imaging abnormalities in temporal lobe epilepsy
119. Regional brain glucose metabolism in patients with complex partial seizures investigated by intracranial EEG
120. Electrocorticographic confirmation of focal positron emission tomographic abnormalities in children with intractable epilepsy
121. Quantifying interictal metabolic activity in human temporal lobe epilepsy
122. Neuroimaging in patients with seizures of probable frontal lobe origin
123. Interictal cerebral metabolism in partial epilepsies of neocortical origin
124. Temporal lobe hypometabolism on PET: Predictor of seizure control after temporal lobectomy
125. Temporal lobectomy for uncontrolled seizures: The role of positron emission tomography
126. Predictors of outcome after anterior temporal lobectomy: Positron emission tomography
127. Presurgical evaluation of temporal lobe epilepsy using interictal temporal spikes and positron emission tomography
128. Quantitative analysis of 18FDG-PET in the presurgical evaluation of patients suffering from refractory partial epilepsy. Comparison with CT, MRI, and combined subdural and depth EEG
129. Presurgical evaluation for partial epilepsy: Relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG
130. Functional neuroimaging strategy in temporal lobe epilepsy: A comparative study of 18FDG-PET and 99mTc-HMPAO-SPECT
131. FDG-PET and volumetric MRI in the evaluation of patients with partial epilepsy
132. Complex partial seizures: Cerebellar metabolism
133. PET and functional testing in temporal lobe epilepsy
134. The Lennox-Gastaut syndrome: Metabolic subtypes determined by 2-deoxy-2[18F]fluoro-D-glucose positron emission tomography
135. Surgical treatment of intractable neonatal-onset seizures: The role of positron emission tomography
136. Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment
137. Mesiobasal versus lateral temporal lobe epilepsy: Metabolic differences in the temporal lobe shown by interictal 18F-FDG positron emission tomography
138. Complex partial seizures. Correlation of clinical and metabolic features
139. Interictal metabolic anatomy of mesial temporal lobe epilepsy
140. Subcortical metabolic alterations in partial epilepsy
141. Asymmetric interictal glucose hypometabolism and cognitive performance in epileptic patients
142. Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy
143. Magnetic resonance imaging and positron emission tomography of band heterotopia
144. Brain glucose utilization in band heterotopia: Synaptic activity of "double cortex"
145. MR imaging and positron emission tomography of cortical heterotopia
146. PET, CT, and MRI imaging of neuronal migration anomalies in epileptic patients
147. Neuronal migration disorders: Positron emission tomography correlations
148. Hemimegalencephaly: Evaluation with positron emission tomography
149. Hypometabolic cortical lesions in tuberous sclerosis with epilepsy: Demonstration by positron emission tomography
150. Complex partial seizures: Cerebral structure and cerebral function
151. Left hemispheric neuronal heterotopia: A PET, MRI, EEG and neuropsychological investigation of a university student
152. Ictal patterns of cerebral glucose utilization in children with epilepsy
153. Epilepsia partialis continua studied by PET
154. The dynamics of metabolic change following seizures as measured by positron emission tomography with fluoro-deoxyglucose F18
155. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci
156. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci
157. [11C]Flumazenil positron emission tomography: An in vivo marker of neuronal loss in temporal lobe epilepsy
158. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy
159. In-vivo 11C-flumazenil PET correlates with ex-vivo 3H-flumazenil autoradiography in hippocampal sclerosis
160. Absolute PET quantification with correction for partial volume effects within cerebral structures
161. Regional hippocampal [11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis
162. [11C]Flumazenil positron emission tomography visualizes frontal epileptogenic regions
163. 11C-flumazenil PET in neocortical epilepsy
164. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: A positron emission tomography study
165. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients
166. Involvement of intrathalamic GABA-B transmission in the control of absence seizures in the rat
167. Benzodiazepine-GABAA receptors in idiopathic generalised epilepsy measured with [11C]flumazenil and positron emission tomography
168. Cortical benzodiazepine receptor binding in patients with generalized and partial epilepsy
169. In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy
170. Evidence for a critical role of GABAergic transmission within the thalamus in the genesis and control of absence seizures in the rat
171. Benzodiazepine-GABAA receptor binding during absence seizures
172. Neuropeptides: Anticonvulsant and convulsant mechanisms in epileptic model systems and in humans
173. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy
174. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography
175. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography
176. PET imaging of opiate receptor binding in human epilepsy using [18F]cyclofoxy
177. Focal cortical release of endogenous opioids during reading-induced seizures
178. Positron emission tomography with [11C] deuterium-deprenyl in temporal lobe epilepsy
179. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy
180. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]-methyl-L-tryptophan positron emission tomography
181. Histamine H1 receptors in complex partial seizures
182. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis